Reading TCRT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TCRT free→Reading TCRT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TCRT free→QuarterlyIQ Insights · TCRT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the…
Other Events. Shareholder Nomination of Potential Board Member The Company notes the following developments regarding a group of stockholders (the “Group”) that has filed Schedules 13D with the Securities and Exchange Commission: ▪ On October 30, 2025, the Group filed an initial Schedule 13D reporting beneficial ownership of approximately 8.6% of the Company’s outstanding common stock. The filing stated the Group’s intention to engage with the Board of Directors to discuss potential ways to e…
Material Modification to Rights of Security Holders. On January 8, 2026, the Board of Directors of the Company approved and adopted Amended and Restated By-Laws of the Company (the “Amended and Restated Bylaws”), effective immediately. The Amended and Restated Bylaws include, among other changes: ▪ A new Article 2, Section 2.14 establishing comprehensive procedures and requirements for stockholder nominations of director candidates and proposals of other business to be brought before annual a…
Termination of a Material Definitive Agreement. On January 8, 2026, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor”) terminating, effective immediately, the engagement letter dated August 14, 2023 (the “Engagement Letter”), pursuant to which Cantor had been engaged as the Company’s exclusive financial advisor in connection with the exploration of potential strategic transactions. The Engagement Letter provided that it could be terminated by the Company on or after th…
Entry into a Material Definitive Agreement On December 17, 2025, Alaunos Therapeutics, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) resolving all disputes related to unpaid invoices under the 2019 Research and Development Agreement. Under the Settlement Agreement, the Company agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding invoices…
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Michael A. Jerman On July 15, 2025, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Mr. Michael A. Jerman, as a director of the Company effective immediately. Mr. Jerman fills the vacancy created by Mr. Dale Curtis Hogue’s resignation. Mr. Jerman was also appointed to the Audit Committee and the Compensation Committee of the Board, replacing Mr. Holger Wei…
Material Modification to Rights of Security Holders. At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Alaunos Therapeutics, Inc. (the “Company”), held on July 3, 2025, and as further described in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As a result of voluntary resignation of Mr. Weis as the chairman of the Audit Committee and as a member of the Compensation Committee, as described in more detail in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Dale Curtis Hogue, Jr. as Chief Executive Officer and Director On July 1, 2025, Dale Curtis Hogue, Jr. notified the Company of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) and his position as Chief Executive Officer, effective immediately. His departure was not due to any disag…
Unregistered Sales of Equity Securities . The information set forth above in
of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD. Forward-Looking Information This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminolo…
Material Modification to Rights of Security Holders. The information set forth in
Entry into a Material Definitive Agreement Subscription Agreement On June 24, 2025, Alaunos Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Subscription Agreement (the “Agreement”), by and among the Company and the purchasers listed on Appendix A therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private offering to the Purchasers shares of Series A-2 Convertible Preferred Stock of the Company, par value of $0.001 per share (the…
Entry into a Material Definitive Agreement. Securities Purchase Agreement for Registered Direct Offering On June 20, 2025, Alaunos Therapeutics, Inc. (the “Company”) entered in a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers identified therein, pursuant to which the Company agreed to issue and sell (i) 338,725 shares of common stock (the “Shares”), par value $0.001 per share of the Company (“Common Stock”), at a purchase price of $3.36 per share;…
Entry into a Material Definitive Agreement As previously disclosed, on May 19, 2025, Alaunos Therapeutics, Inc., a Delaware corporation (the “Company”) issued to Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”) a warrant to purchase 79,900 shares of the Company’s common stock (the “Warrant”), concurrently with the execution of an equity purchase agreement and a registration rights agreement by the Company and Mast Hill. On June 9, 2025, the Company entered into an Amendment…
Unregistered Sales of Equity Securities The information contained in
Unregistered Sales of Equity Securities The information contained in
Entry into a Material Definitive Agreement On May 19, 2025, Alaunos Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an equity purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), pursuant to which Mast Hill has committed to purchase up to $25.0 million of the Company’s common stock, par value $0.001 per share (the “Common Stock”).…
Departure of Directors or Certain Officers Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect. Dr. Hofmeister’s resignation was not the result of any disagreement on any matter relating to the Company’s operations, policies or practices. . SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caus…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 13, 2025, the Board of Directors of Alaunos Therapeutics, Inc. (the “Company”) elected to receive compensation in equity rather than in cash for their cumulative deferred board service fees, as permitted under the Company’s Non-Employee Directors Compensation Policy. The total deferred board service fees amounted to $139,000, accrued from…
Material Modification to Rights of Security Holders. The information set forth in
Entry into a Material Definitive Agreement Subscription Agreement On April 11, 2025, Alaunos Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Subscription Agreement (the “Agreement”), by and among the Company and Watermill Asset Management set forth on Appendix A thereto, pursuant to which the Company agreed to issue and sell, in a private offering to the Purchaser shares of Series A-1 Convertible Preferred Stock of the Company, par value of $0.001 per share (the “Ser…
Unregistered Sales of Equity Securities . The information set forth above in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 7, 2025, Alaunos Therapeutics, Inc., (the “Company”) received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024 (the “2024 10-K”), did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1)…
Importance-ranked changes since the prior daily snapshot.
Composite insight fell by 13.8 points (from -12.2 to -26.0).
Valuation label changed from 'None' to 'expensive'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.